| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 1.3K | 11.3% |
| Total Income | 1.3K | 11.8% |
| Expenditure | 997.85 | 8.6% |
| PBT | 331.13 | 22.9% |
| Net Profit | 255.34 | 13.3% |
| OPM | 26.97% | 1.58pp |
| NPM | 19.21% | 0.26pp |
| EPS | 20.44 | 13.6% |
Ajanta Pharma Reports 14% Increase in Q1 FY 2026 Revenue
28 Jul 2025 · 28 Jul 2025, 03:07 pm
Summary
Ajanta Pharma Ltd., a specialty pharmaceutical formulation company, reported an excellent performance for the first quarter ended 30 June 2025. The company's revenue from operations stood at Rs. 1,303 cr., up 14% from the same period last year. EBITDA was at Rs. 351 cr., up 6%, and profit after tax was at Rs. 255 cr., up 4%. Excluding the impact of mark-to-market forex loss, EBITDA stood at Rs. 376 cr., reflecting a 14% growth, with an EBITDA margin of 29%. PAT grew by 12%, with a PAT margin of 21%. Cashflow from operations was Rs. 282 cr., and free cashflow was Rs. 209 cr.
Key Highlights
- 1
Revenue from operations up by 14% (1st Quarter FY 2026)
- 2
EBITDA at 27%
- 3
Profit after tax at 20%
- 4
EBITDA stood at Rs. 376 cr., reflecting a 14% growth
- 5
PAT grew by 12%
- 6
ROCE stood at a healthy level of 33% and RONW at 26%
- 7
India branded generic performance exceeded IPM growth by 29%
Management Comments
Not specified
No specific management comments were provided in the document.
Informational and educational content only. Not investment advice.